Voretigene neparvovec-rzyl for the treatment of biallelic RPE65 mutation–associated retinal dystrophy

  title={Voretigene neparvovec-rzyl for the treatment of biallelic RPE65 mutation–associated retinal dystrophy},
  author={Stephen R. Russell and Jean Bennett and Albert M. Maguire and Katherine A High},
  journal={Expert Opinion on Orphan Drugs},
  pages={457 - 464}
ABSTRACT Introduction: Inherited retinal dystrophies (IRDs) are the major cause of familial blindness in the Western world, and until recently, have been devoid of pharmacologic treatment options. Biallelic mutations in the RPE65 gene cause a progressive IRD characterized by decreased light sensitivity, constricted visual fields, and impaired visual acuity. Voretigene neparvovec-rzyl (VN), an adeno-associated viral vector gene therapy that delivers a normal copy of the RPE65 gene to retinal… 

A Systematic Review and Meta-Analyses of Interventional Clinical Trial Studies for Gene Therapies for the Inherited Retinal Degenerations (IRDs)

FST improvements demonstrate a proof-of-principle for treating IRDs with gene therapy, although comparison by meta-analysis is compromised by, amongst other issues, a variable amount of vector delivered in each trial.

Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders

The history and development of twenty approved human gene and cell-based gene therapy products that have been approved up-to-now are reviewed in clinic and markets of mainly North America, Europe and Asia.

Emerging Gene Manipulation Strategies for the Treatment of Monogenic Eye Disease

Despite setbacks, the licensing of Luxturna for the treatment of RPE65-mediated Leber congenital amaurosis (LCA) is a major advance in efforts to treat these rare, but devastating, causes of visual loss.



Long-term effect of gene therapy on Leber's congenital amaurosis.

In dogs, RPE65 gene therapy with the same vector at lower doses improved vision-guided behavior, but only higher doses resulted in improvements in retinal function that were detectable with the use of ERG, and comparison with the results obtained in the dog model indicates that there is a species difference in the amount of R PE65 required to drive the visual cycle.

Results at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy.

Visual acuity and static perimetry testing results suggest that treating patients at a younger age is associated with better visual function outcomes during 5 years after treatment.

Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement

It is shown that gene therapy improves vision for at least 3 y, but photoreceptor degeneration progresses unabated in humans, and in the canine model, the same result occurs when treatment is at the disease stage equivalent to humans.

RPE65: Role in the Visual Cycle, Human Retinal Disease, and Gene Therapy

Based on several encouraging reports from animal models, at least three clinical trials are currently underway for the treatment of LCA using modified AAV vectors carrying the RPE65 cDNA and have reported positive preliminary results.

Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics

It is found that the intervention could overcome nearly all of the loss of light sensitivity resulting from the biochemical blockade, however, this reconstituted retinoid cycle was not completely normal.

Safety and Proof-of-Concept Study of Oral QLT091001 in Retinitis Pigmentosa Due to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT)

Measuring the outer segment length of the photoreceptor layer with high-definition optical coherence tomography was highly predictive of treatment responses with responders having a significantly larger baseline outer segment thickness than non-responders.